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Edited by Lukas HuberAbstract The apoptotic signals activated by As2O3 in the
chronic myelogenous leukemia (CML) cell lines K562 and
KCL22 were investigated. As2O3 was found to induce apoptosis
in these cells via the intrinsic pathway. As2O3 also induced a
sustained c-Jun NH2-terminal kinase (JNK) activation which
preceded and was necessary for caspase-9 activation. We
established that Rho and its eﬀector, the kinase ROCK, are acti-
vated by As2O3. Inhibition of either Rho or ROCK prevented
JNK activation and protected against apoptosis. Thus, in
CML cells, apoptosis induced by As2O3 is mediated, at least
in part, via a Rho-ROCK-JNK axis. These ﬁndings deﬁne a
novel signaling pathway for As2O3-induced apoptosis.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Mechanisms of arsenic trioxide (As2O3)-induced cell death
are not completely elucidated. A crucial role for the CD95/
CD95L system in As2O3-induced apoptosis has initially been
suggested [1]. In contrast, other studies established that
As2O3 acts in a CD95, caspase-8 and FADD independent fash-
ion [2] and most reports favor the notion that As2O3 triggers
apoptosis via the intrinsic, mitochondrial pathway [3,4]. Gen-
eration of intracellular reactive oxygen species [5] and modula-
tion of the glutathione redox system [6] have been reported to
sensitize leukemic cells to apoptosis during As2O3 treatment.
Activation of p38 and inactivation of ERK might also be
involved [7]. Finally, an essential role for JNK activation as
a mediator of As2O3-induced apoptosis has been shown in
acute promyelocytic [8] and acute myeloid leukemia cells [9].
Most of the above reports dealing with the molecular path-
ways activated by As2O3 concern acute promyelocytic leuke-
mia (APL) cells. However, chronic myelogenous leukemia
(CML) cells, known to be resistant to a number of apoptoticAbbreviations: APL, acute promyelocytic leukemia; CML, chronic
myelogenous leukemia; JNK, c-Jun NH2-terminal kinase; MAPK,
mitogen-activated protein kinase; DN MKK, dominant negative
MAPK kinase; MLC, myosin light chain; GEF, guanine nucleotide
exchange factor
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doi:10.1016/j.febslet.2006.12.016stimuli, were found to be sensitive to the apoptotic eﬀects of
As2O3 [10]. The current study was designed to assess the mech-
anisms of As2O3-induced apoptosis in CML cells. We estab-
lished that apoptosis is induced via the intrinsic pathway.
Substantial and prolonged activation of JNK proved to be
necessary for the death-promoting activity of As2O3. We then
identiﬁed the signaling pathway leading to JNK activation and
found that it was atypical inasmuch as it involves the small
GTPase Rho and its eﬀector, the ROCK kinase.2. Materials and methods
2.1. Cells and reagents
K-562 and KCL22 [11], BCR-ABL positive cell lines derived from
patients with CML and K6, a K-562 clone stably overexpressing
Bcl-2 were used [12]. They were routinely maintained in RPMI 1640
(Life Technologies) supplemented with 10% fetal calf serum, 1%
sodium pyruvate, 0.1 mg/ml streptomycin, 100 U/ml penicillin at
37 C in a 5% CO2 humidiﬁed atmosphere.
As2O3 (Sigma–Aldrich) was dissolved in 1 N NaOH to generate a
10 mM stock solution. Q-VD-OPH (MP Biomedicals), a pan-caspase
inhibitor and Z-IETD-fmk (Bachem), a speciﬁc caspase-8 inhibitor
were used at 20 lMwith a 2 h pre-incubation time. The ERK inhibitor
U0126 (Promega) and the p38 inhibitor SB 203580 (Calbiochem) were
used at 20 lM with a 30 min pre-incubation time. The cell-permeable
peptide inhibitor of JNK, D-JNKI-1 [13], kindly provided by Xigen
SA (Lausanne, Switzerland), was used at 30 lM with an overnight
pre-incubation time. Y-27632 (Calbiochem), a selective ROCK inhibi-
tor, was used at 20 lMwith a 2 h pre-incubation time. TAT-C3, a cell-
permeable protein inhibitor of Rho, was prepared in the laboratory as
described [14] and used at 50 lg/ml with a 4 h pre-incubation time.
The following antibodies were used: anti-caspase-8 (Alexis), anti-
caspase-9, anti-cleaved caspase-3, anti-phospho-JNK Thr183/Tyr185,
anti-JNK, anti-phospho-c-jun (ser 63), anti-c-jun, all from Cell
Signaling, anti-ppMLC (a kind gift of J.M. Staddon, Eisai, London),
anti-Hsc70 (Santa-Cruz), anti-RhoA (clone 26C4, produced in the
laboratory [15]).2.2. Apoptosis
Apoptotic cells were quantiﬁed by ﬂow cytometry with propidium
iodide (PI, Sigma). Cells were incubated overnight in 70% ethanol at
20 C and stained with PI (50 lg/ml in PBS). Data acquisition was
performed on a FACSCalibur ﬂow cytometer and analysis was done
with the CellQuest software (Becton Dickinson). Pseudo-hypodiploid
apoptotic cells display sub-G1 DNA content.
Apoptotic cells were also quantiﬁed by ﬂuorescence microscopy
after staining with 5 lg/ml Hoechst 33342 (Sigma). The percentage
of cells with condensed chromatin and/or fragmented nuclei was
assessed by counting at least 400 cells in diﬀerent ﬁelds.2.3. Western blotting
For detection of JNK and c-jun , cells were lysed in Triton buﬀer
(20 mM Tris, pH 7.4, 1% Triton X-100, 137 mM NaCl, 2 mM tetraso-
dium pyrophosphate, 2 mM EDTA, 10% glycerol, 1 mM sodiumblished by Elsevier B.V. All rights reserved.
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phonyl ﬂuoride (PMSF) and 10 lg/ml leupeptin). For detection of
caspases and myosin light chain (MLC), cells were lysed in Lae¨mmli
buﬀer (60 mM Tris, pH 6.8, 10% glycerol and 2% SDS) and lysates
were sonicated gently on ice. All lysates were clariﬁed by centrifugation
at 18000 · g for 15 min at 4 C. Proteins were separated by SDS–
PAGE and blots were probed with appropriate combination of
primary and HRP-conjugated secondary antibodies. Proteins were
visualized by enhanced chemiluminescence (ECL, Amersham).2.4. RhoA-GTP pull-down assay
The Rho-binding domain of Rhotekin (RBD) was expressed in
Escherichia coli with the use of pGEX-2T (Pharmacia) encoding
GST-fusion proteins as described [14].
Cells were lysed in RIPA buﬀer (50 mM Tris, pH 7.2, 1% Triton X-
100, 0.5% deoxycholic acid, 0.1% SDS, 500 mM NaCl, 10 mM MgCl2,
1 mM PMSF and 10 lg/ml each leupeptin and aprotinin). Cell lysates
were clariﬁed by centrifugation at 18000 · g for 15 min at 4 C and
equal volumes of lysates were incubated with GST-RBD beads at
4 C for 45 min. The beads were washed with RIPA buﬀer and proteins
associated with GST-RBD bound to beads were boiled and separated
by SDS–PAGE. Immunoblotting was carried out using a speciﬁc anti-
RhoA monoclonal antibody.2.5. Measurement of transcriptional activity using dual-luciferase
reporter assay
Luciferase reporter plasmid pFR-Luc (5 · Gal4 binding site) and the
fusion trans-activator plasmid pFA2-cJun (pCMV-Gal4-cJun) were
from Stratagene. pcDNA3-Flag-DN MKK4 [16] and pcDNA3-Flag-
DN MKK7 [17] were used and normalization was performed with a
psRa-Renilla luciferase reporter [18].
Cells were transiently transfected using a gene pulser apparatus
(Bio-Rad Laboratories, Hercules, CA, USA) set at 250 V and
960 lF. Cells (107) were electroporated with 6 lg of plasmid DNA:
0.05 lg of pFA2-cJun, 1 lg of 5 ·Gal4-luciferase reporter, 2 lg oft
b
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Fig. 1. Bcl-2 expression prevents As2O3-induced apoptosis in K562. K562 and
(a) Flow cytometric analysis of cellular DNA content after staining with pro
DNA content. Results are the means ± S.D. of three separate experiments.
fragmentation as assessed by microscopic examination after Hoechst 33342 st
(20 lM) and K6 cells were incubated with As2O3 (10 lM) for the indicated ti
(55/53 kD) or cleaved (43/41 kD) caspase-8 were identiﬁed by Western-blottpcDNA3-DN MKK4 or 2 lg of pcDNA3-DN MKK7 when required
and 0.05 lg psRa-Renilla luciferase reporter. The total amount of
transfected DNA was kept constant by addition of control empty
vector.
Protein extracts were prepared using Passive Lysis Buﬀer (Promega)
to proceed to a dual luciferase assay, following manufacturer’s instruc-
tions. Luciferase activity in 10 ll of the lysates was measured on a
MicroLumat Plus LB 96 V Luminometer (Berthold Technologies,
Thoiry, France). Results were analyzed by dividing ﬁreﬂy signals by
Renilla signals and expressed as fold increase or percent maximal
induction, relative to the basal activity measured in untreated cells
transfected with empty control vector. Data represent the
means ± S.D. of three independent experiments.3. Results
3.1. As2O3 induces apoptosis via the intrinsic pathway in K562
cells
In order to deﬁne whether mitochondria are involved in
As2O3-induced apoptosis in CML cells, the percentage of
apoptotic cells was determined in K562 cells exposed to
10 lM As2O3 for 48 h compared to a K562 clone engineered
to stably express Bcl-2 (K6) [12]. As shown in Fig. 1a, overex-
pression of Bcl-2 reduced the percentage of apoptotic cells as
deﬁned by cells with hypodiploid DNA content. Similar results
were obtained when apoptotic cells were identiﬁed by micro-
scopic examination (Fig. 1b). These results support a critical
role of mitochondria as a gatekeeper. The activation of cas-
pase-9 and caspase-8 was then studied in kinetics during
As2O3 exposure. Fig. 1c and d shows that both caspase-9
and caspase-8 were cleaved and thus activated in K562 cells.ime (h) 24 48 24 48

































K6 (K562 Bcl-2) were incubated with As2O3 (10 lM) for 24 h or 48 h.
pidium iodide. Data represent the percentage of cells with hypodiploid
(b) Percentage of cells with chromatin condensation and/or nuclear
aining (mean ± S.D.; n = 3). K562 pre-treated or not with Z-IETD-fmk
mes. (c) Native (47 kD) or cleaved (35/37 kD) caspase-9 and (d) native
ing.
Time (h) 0 0.25 0.5 1 2
Time (h) 2 6 24 2 6 24
















120 S. Potin et al. / FEBS Letters 581 (2007) 118–124However, blockade of caspase-8 with the speciﬁc Z-IETD-fmk
inhibitory peptide did not prevent caspase-9 activation as
would be expected if caspase-8 was at the apex of apoptotic
signaling (Fig. 1c and d). In contrast, caspase-8 was not
cleaved in the K6 clone (Fig. 1d) conﬁrming that its activation
occurs subsequently to mitochondrial events and not as a re-
sult of death receptor activation. In addition, we found that
Bax is activated and relocalized to mitochondria in As2O3-
treated K562 cells (not shown). Together, these data indicate
that As2O3 induces apoptosis in CML cells via the intrinsic
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Fig. 2. As2O3 induces a rapid and sustained activation of JNK. (a,b)
K562 cells were treated with As2O3 (10 lM) for the indicated times.3.2. As2O3 induces a sustained activation of JNK in K562 cells
Several lines of evidence demonstrate that one of the triggers
of apoptosis via the mitochondria-dependent pathway is the
JNK cascade [19–22]. We therefore examined the eﬀect of
As2O3 on JNK activation in K562 cells. JNK1 and JNK2 were
found to be phosphorylated, and thus activated, as soon as 1 h
after exposure to As2O3 (Fig. 2a). This activation was sus-
tained and persisted throughout the observation time, i.e.
24 h (Fig. 2b). JNK was phosphorylated in the K6 clone as
well (not shown), thus indicating that its activation by As2O3
occurs even in cells where caspases are not activated.
Since JNK phosphorylation does not always reﬂect full acti-
vation of JNK, we also analysed regulation of the mitogen-
activated protein kinase (MAPK) pathway by monitoring
c-Jun transactivation by As2O3. As shown in Fig. 2c, As2O3
produced a dose dependent increase in luciferase expression
with an increase of about 10-fold at 10 lM and 2-fold at the
therapeutic concentration of 2 lM. Thus, As2O3 induces
JNK activation also at clinical concentration.
We then investigated the pathway by which As2O3 activates
JNK. Two MAP2Ks, SEK/MKK4 and MKK7, for JNK have
been identiﬁed [23]. We studied c-Jun transactivation by As2O3
after transfection of dominant negative (DN) MKK4 and DN
MKK7. Each of these constructs reduced by 29% the As2O3-
induced increase in luciferase gene activity (Fig. 2d). When
added in combination, DN MKK4 and DN MKK7 inhibited
by 65% the increase in reporter gene activity (Fig. 2d). These
data show that both MKK4 and MKK7 are involved in
As2O3-induced JNK activation in K562 cells.
Phosphorylated JNK was probed by Western-blot analysis using anti-
phospho-JNK antibody. Total JNK was used as a loading control. (c)
Dose-dependent transactivation of pFA2-cJun by As2O3. K562 cells
were transfected with 1 lg of 5 · Gal 4 luciferase reporter, 0.05 lg of
pFA2-cJun and 0.05 lg of pSRa-Renilla standardization reporter.
Cells were then treated with increasing concentrations of As2O3 for
16 h. Results are expressed in normalized RLU and represent the
means ± S.D. for at least three independent experiments. (d) Expres-
sion of DN MMK4 and DN MKK7 decreased the Gal4-cJun-induced
luciferase activity in response to As2O3. K562 cells were co-transfected
with 2 lg of plasmids coding for DN MMK4 and DN MKK7, 1 lg of
pFR-Luc, 0.05 lg of pFA2-cJun and 0.05 lg of pSRa-Renilla and then
treated with 10 lM As2O3 for 16 h. The total amount of transfected
DNA was kept constant by addition of empty control vector. Results
are expressed as the means ± S.D. for at least three independent
experiments.3.3. JNK is involved in As2O3-induced apoptosis in K562 cells
To determine whether JNK activation plays a role in As2O3-
induced apoptosis, JNK inhibitor-1 (JNKI1), a speciﬁc cell-
permeable peptide inhibitor of JNK activity [13], was utilized.
We used the D-form of this peptide because our initial experi-
ments with the more common L-form were unsuccessful (not
shown). Compared to L-JNKI-1, D-JNKI-1 has the speciﬁcity
of being protease-resistant [13]. A 16 h pre-incubation with D-
JNKI-1 (30 lM) was found to be eﬃcient in inhibiting JNK
activity in K562 cells exposed to As2O3, as judged by the
reduction of c-Jun phosphorylation (Fig. 3a). In the presence
of D-JNKI-1, As2O3-induced apoptosis was inhibited
(Fig. 3b) thus demonstrating that JNK is involved in the apop-
totic signaling triggered by As2O3 in CML cells. Moreover,
D-JNKI-1 prevented the activation of caspase-9 (Fig. 3c) indi-
cating that JNK site of action is upstream of mitochondrial
perturbations. Caspase-3 activation was inhibited as well by
D-JNKI-1 (Fig. 3c).To determine whether other MAPK could also be impli-
cated, we treated cells with As2O3 in the presence of the
ERK inhibitor U0126 or the p38 inhibitor SB 203580. Neither
of these compounds reduced the percentage of apoptotic cells
and in fact U0126 slightly increased it (not shown).
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Fig. 3. JNK is involved in As2O3-induced apoptosis. K562 cells,
pretreated with D-JNKI-1 (30 lM) overnight, were incubated with
As2O3 (10 lM) for the indicated times. (a) JNK activity was
determined by Western-blot analysis using anti-phospho-c-jun anti-
body. Hsc 70 was used as a loading control. (b) Apoptotic cells were
enumerated as in Fig. 1b. One experiment representative of three
independent experiments is shown. (c) Blots were probed with
antibodies against caspase-9 and cleaved caspase-3.
Time (h) 0 0.5 1 2 0 0.5 1 2
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Fig. 4. JNK is phosphorylated in a Rho- and ROCK-dependent
manner. K562 cells were treated with As2O3 (10 lM) for the indicated
times. (a) Pull-down assay with GST-fusion proteins of the rho-
binding domain (RBD) was performed. The active GTP-bound Rho
precipitated from lysates was detected by western-blotting with anti-
RhoA antibody. (b,c) K562 cells, pretreated where indicated with
50 lg.ml1 TAT-C3 for 4 h, 20 lM Y-27632 for 2 h or 20 lM Q-VD-
OPH for 2 h, were incubated with As2O3 (10 lM) for 1 h. Cells lysates
were analysed by Western blotting with antibody against phosphor-
ylated MLC (PP-MLC) or MLC (charge control). (d) K562 cells were
pretreated and incubated as described above. Blots were probed with
anti-phospho-JNK and anti-JNK (charge control) antibodies.
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Rho-ROCK cascade
Recent evidence indicates that the small GTPase Rho can in
some instances control the activity of the JNK cascade [24,25].
Therefore, the level of the active GTP-bound form of RhoA
was measured in kinetics in K562 cells exposed to As2O3. As
shown in Fig. 4a, Rho was activated in a sustained manner
as soon as 30 min after As2O3 exposure. There was no change
in the level of total Rho in these cells (Fig. 4a). We then inves-
tigated the status of the serine-threonine kinase ROCK, one of
the major eﬀectors of Rho. ROCK was activated in K562 cells
treated with As2O3, as evidenced by increased phosphorylation
of its substrate MLC (Fig. 4b). As expected, this phosphoryla-
tion was abrogated in presence of the ROCK inhibitory com-
pound, Y-27632 (Fig. 4b). We have previously shown that, in
apoptotic cells, ROCK can be activated in a Rho-independent
pathway following its cleavage by caspase-3 that removes an
inhibitory C-terminal peptide [14]. Such was not the case here
as MLC phosphorylation preceded caspase activation and was
abrogated by Rho-inhibition with TAT-C3 (Fig. 4b). More-
over, MLC phosphorylation was not aﬀected by caspase inhi-
bition with the pan-caspase inhibitor Q-VD-OPH (Fig. 4c).
Together, these results indicate that exposure to As2O3 triggers
a classical Rho-ROCK cascade in CML cells.
We then tested whether Rho and ROCK could be involved
in JNK activation by As2O3. Inhibition of Rho with TAT-C3
diminished JNK phosphorylation (Fig. 4d) thus indicating
that, in As2O3-treated cells, JNK activation is dependent upon
Rho activity. Inhibition of ROCK with the Y-27632 com-
pound also lead to a reduction of JNK phosphorylation
(Fig. 4d). Together, these data show that in K562 cells treated
with As2O3 JNK activation is mediated, at least in part, via the
Rho-ROCK pathway.3.5. Inhibition of Rho or ROCK protects against As2O3-induced
apoptosis in K562 cells
In order to test whether Rho and ROCK are involved in
As2O3-induced apoptosis, the percentage of apoptotic cells
was evaluated in As2O3-treated cells in which either Rho or
ROCK was inhibited. Inhibition of either Rho with TAT-C3
or ROCK with Y-27632 reduced the apoptotic response as
measured by quantiﬁcation of cells with chromatin condensa-
tion (Fig. 5a) or hypodiploid DNA content (Fig. 5b). As a
proof of a direct relationship between ROCK and apoptotic
signaling, ROCK inhibition with Y-27632 inhibited caspase-9
activation (Fig. 5c). As a consequence, caspase-3 activation
was abrogated as well (Fig. 5c). Taken together, these data
demonstrate that As2O3-induced apoptosis is mediated in part
through the activation of JNK by a Rho-ROCK signaling axis.
3.6. A Rho-ROCK pathway is involved in As2O3-induced
apoptosis in CML cells KCL22
In order to test whether our ﬁndings could be generalized to
other CML cells, we used the KCL22 cell line [11]. As shown in
Fig. 6a, JNK was activated in KCL22 cells during As2O3 expo-
sure in a Rho-dependent manner. We then investigated
whether inhibition of the Rho-ROCK pathway could inﬂuence
caspase-activation and found that inhibition of ROCK re-
duced caspase-9 as well as caspase-3 cleavage (Fig. 6b). Final-
ly, treating As2O3-exposed KCL22 cells with the Y-27632
compound signiﬁcantly diminished the percentage of cells
undergoing apoptosis (Fig. 6c). Thus these results are similar
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Fig. 5. Involvement of Rho and ROCK in As2O3-induced apoptosis.
K562 cells, pretreated where indicated as in Fig. 4b, were incubated
with As2O3 (10 lM) for 24 h. (a) Apoptotic cells detected by
microscopic examination (means ± S.D.; n = 3). (b) Flow cytometry
analysis of DNA content. Data are representative of ﬁve independent
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Fig. 6. A Rho-ROCK-JNK pathway is involved in As2O3-mediated
apoptosis in KCL22 cells. KCL22 cells, pretreated where indicated as
in Fig. 4b, were incubated with As2O3 (10 lM). (a) JNK phosphor-
ylation analyzed as in Fig. 4d. (b) Blots were probed with antibody
against caspase-9 and cleaved caspase-3 after 24 h of incubation with
As2O3. (c) Percentage of apoptotic cells after 24 h of incubation with
As2O3 measured by microscopic examination.
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The aim of the present work was to investigate the molecular
mechanisms involved in As2O3-induced apoptosis in CML
cells. We show that, in K562 cells, apoptosis is triggered via
the intrinsic pathway inasmuch as caspase-9 is activated even
when caspase-8 is inhibited. Moreover, caspase-8 is not cleaved
in a Bcl-2 expressing K562 clone, indicating that its activation
occurs downstream of mitochondrial events. In line with these
data, cells that express Bcl-2 are resistant to As2O3-triggered
cell death.
We found that As2O3 induces a rapid activation of JNK1
and JNK2 starting after one hour of incubation. The func-
tional consequences of JNK activation are known to be cell
type and signal speciﬁc and this signaling pathway contributes
to the regulation of cell proliferation as well as apoptosis [23].
These opposite functions appear to correlate with the time
course of JNK activation as sustained but not transient activa-
tion is associated with apoptosis [26]. In our experiments, JNK
activation by As2O3 was sustained, lasting at least 24 h, sug-
gesting that it might be involved in apoptotic signaling. In-
deed, addition of a cell-permeable peptide inhibitor of JNK
abrogated As2O3-induced apoptosis. This peptide also inhib-ited caspase-9 activation indicating that JNK acts upstream
of mitochondrial events.
Small GTPases of the Rho family, Rho, Rac and Cdc42, and
their eﬀectors are mainly known for their role in the regulation
of the actin cytoskeleton during adhesion, cell spreading and
migration [27]. Besides the cell architecture, Rho GTPases
are also involved in gene expression, cell proliferation and cell
transformation [28]. We established that Rho and ROCK are
activated during As2O3 treatment and that interfering with
either Rho or ROCK function inhibits JNK activation as well
as apoptosis induction. Therefore, in CML cells, As2O3-in-
duced apoptosis is in part mediated via a novel Rho-ROCK-
JNK axis. These results place activation of Rho at the apex
of apoptotic signaling, an unusual function for this protein.
It has been reported that scaﬀold proteins govern RhoA-sig-
naling speciﬁcity and two major pathways have been described
linking Rho to JNK activation [29]. In the presence of the scaf-
fold protein hCNK1, the kinases MLK3 and MKK7 lead to
the selective activation of JNK [25]. In the absence of hCNK,
Rho can stimulate JNK via distinct signaling modules which
include a ROCK/MKK4/JNK signaling axis [24]. We do not
know whether the CML cells used in this study express
hCNK1. However, we found that regulation of c-jun activa-
tion by As2O3 in these cells involves both MKK4 and MKK7.
Rho GTPases cycle between an active GTP- and an inactive
GDP-bound state. Binding to GTP is promoted by Rho
guanine nucleotide exchange factors (Rho-GEFs). Thus, the
activation of Rho by arsenic trioxide most likely involves a
Rho-GEF, the identity of which remains to be deﬁned.
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property which might underlie the arrest in metaphase that we
(not shown) and others [31] have observed prior to the entry
into apoptosis. Among the numerous Rho-GEF, GEF-H1
has the unique property to be associated with and maintained
inactive by microtubules [32]. The possibility that release of
GEF-H1 during As2O3 exposure might be responsible for
Rho activation appears worth exploring.
We have performed our study in CML cells but, at the pres-
ent time, the major clinical application of As2O3 is in APL. In
vitro, As2O3 has dose-dependent eﬀects in APL cells; these in-
clude the promotion of partial diﬀerentiation at low concentra-
tions and the induction of apoptosis at higher concentrations
[33]. Cell diﬀerentiation most likely occurs through the degra-
dation of the PML-RARa product and the subsequent release
of the maturational block. On another hand, JNK activation is
a central mediator of the apoptotic response in APL cells [8]. It
would be interesting to deﬁne whether the As2O3-induced
Rho-ROCK-JNK pathway that we have uncovered could be
active in these cells.
The treatment of choice for CML is the tyrosine kinase
inhibitor imatinib mesylate. However, up to 40% of patients
fail to achieve a major cytogenetic response and 60% do not
achieve a complete remission after 18 months of therapy
[34]. This resistance is often due to mutations in the ATP bind-
ing site or to BCR-ABL overexpression [35]. Synergistic pro-
apoptotic eﬀects have been shown in CML cell lines using
the combination imatinib mesylate and As2O3 [36]. Moreover,
resistance to imatinib mesylate does not induce cross-resis-
tance to As2O3 [37]. The combination of imatinib mesylate
and As2O3 is being investigated in a phase I/II multicenter
study in patients with chronic phase CML who did not attain
a complete remission to imatinib mesylate as a single agent
[38]. Therefore, a better deﬁnition of As2O3 mechanism of ac-
tion in CML cells appears particularly relevant at this time.
In conclusion, we have found that As2O3 activates the small
GTPase Rho and that this event initiates apoptotic signaling in
CML cells. These ﬁndings deﬁne a novel signaling pathway for
As2O3-induced apoptosis. They also highlight the pleiotropic
functions of the Rho protein so far mainly known for its
involvement in cell adhesion, migration, proliferation and cell
transformation.
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